In Egypt, the humanitarian obligations Genzyme, to treat all patients with a rare disease Gaucher's the world's first commercial aims is necessary to recoup the huge investment required to bring the drug to market Cerezyme. Here Tomye Tierney must decide how to balance the demands of the sales organization that is facing saturation in developed markets, but also a great opportunity for growth in developing economies. They believe that as long as Gaucher-Genzyme partnership initiative with the project Hope provides free Cerezyme, they will not be able to convince the Egyptian government to allow a refund, which can run from $ 200,000 to $ 300,000 per patient per year. Director General Henri Termeer said Genzyme may hold fast as humanitarian obligations and a strong patient-focused business objectives. But this Tierney, who is on the front line and is negotiating an agreement between Genzyme slim sales, Project Hope, and the Egyptian authorities.
This case is only available in paper format (HBP do not have the rights to distribute digital content). As a result, a digital copy of an educator if not available through this Web site. PLEASE NOTE: This event is accompanied by a short video for Premium Teachers to show in class. To view the video, or to show the students, click on the video icon. "Hide
by Christopher A. Bartlett, Andrey N. McLean Source: Harvard Business School 22 pages. Publication Date: 10 September 2002. Prod. #: 303048-HCB-ENG
Related Case Solutions & Analyses:
Community Health Workers in Zambia: Incentive Design and Management
Communicating in Organizations in the Digital Age
Performance Management at Vitality Health Enterprises, Inc., Spanish Version
Pricing of players in the Indian Premier League
Mario Laborin and the Turnaround of Mexico’s Nacional Financiera (B)
Exit Strategy (A)
Trisha Wilson of Wilson & Associates, Spanish Version
BET.com
Gillette Co. (A): Pressure for Change
Redesigning Work in an Era of Cognitive Technologies
